Skip to content
← Survival collections

ARCHIVED POPULATION DATA

Chronic myeloproliferative disorders (CMD)

Archived November 2024 SEER release. This is relative survival from diagnosis for the published population, not an individual prediction or a treatment-effect estimate.

Relative survival across follow-up

0%25%50%75%100%0246810Years since diagnosis
Exact archived source values · CI = confidence interval
YearRelative survival (%)95% CI lower95% CI upperStandard errorCases
0100Not publishedNot publishedNot published91286
195.929495.761196.09130.084291286
293.434593.211793.65020.111991286
390.926790.658991.18710.134791286
488.411788.104388.71180.15591286
586.206185.863286.54130.17391286
684.085983.709384.45460.190191286
781.830681.420382.23290.207391286
879.557679.113779.99330.224491286
977.456676.979477.92540.241391286
1075.435274.924375.93750.258591286
Permanent reference to this archived population →
Source definitions, footnotes and provenance
age and race caveat
Published age/race categories can overlap. They are selectable strata, not partitions to add together.
cohort count definition
Source Number of Cases, repeated by follow-up row; not people remaining at risk.
content sha256
4fedf5cc02696c8b35f06f1b163ef1c0fa873bfdf6f8ec5b22a980635cb5a0ce
dimensions
Age at Diagnosis
  1. Ages 15-39
  2. Ages 40-64
  3. Ages 50-64
  4. Ages 65+
  5. Ages 65-74
  6. Ages 75+
  7. Ages < 15
  8. Ages < 20
  9. Ages < 50
  10. All Ages
Race/Ethnicity
  1. All Races / Ethnicities
  2. Black (includes Hispanic)
  3. Hispanic (any race)
  4. Non-Hispanic American Indian / Alaska Native
  5. Non-Hispanic Asian / Pacific Islander
  6. Non-Hispanic Black
  7. Non-Hispanic White
  8. White (includes Hispanic)
Sex
  1. Both Sexes
  2. Female
  3. Male
Stage at Diagnosis
  1. All Stages
Years of Diagnosis
  1. 2000-2021
id
cmd-chr-myeloproliferative
immutable id
seer-group:cmd-chr-myeloproliferative@4fedf5cc02696c8b35f06f1b163ef1c0fa873bfdf6f8ec5b22a980635cb5a0ce
method
Relative survival calculated using monthly intervals; table publishes annual landmarks from diagnosis through year ten.
missing value definition
Source dash (-) does not differentiate suppression, unavailable data, or other missingness. No suppression reason is inferred.
normalized source
file
normalized/followup/cmd-chr-myeloproliferative.json.gz
sha256
db4b840d731ca59ed08b32f158572a738262fd70dfd7db9da690bf6dbf3090d7
period interpretation
The displayed diagnosis period is the source table label. Exact case-eligible years are not inferred from it.
registry
SEER 21 (excluding Illinois)
sheet
CMD, Chr. myeloproliferative...
site
Chronic myeloproliferative disorders (CMD)
source
bytes
45275886
file
raw/Survival by Survival Time, November 2024.xlsx
retrieved at
2026-09-09T23:23:39.141323+00:00
sha256
4300662c48518fc384f68c039c8bbcd2a072e603576b36d327e6b17f80771e34
title
Survival by Survival Time
source footnotes
  1. row
    2648
    values
    1. Footnotes
  2. row
    2649
    values
    1. Data Source:
  3. row
    2650
    values
    1. -SEER Incidence Data, November 2024 Submission (1975-2022), SEER 21 registries [https://seer.cancer.gov/registries/terms.html] (excluding Illinois).
  4. row
    2651
    values
    1. -Expected Survival Life Tables [https://seer.cancer.gov/expsurvival/] by Socio-Economic Standards.
  5. row
    2652
    values
    1. Methodology:
  6. row
    2653
    values
    1. -The relative survival rates are calculated using monthly intervals.
  7. row
    2654
    values
    1. Race/Ethnicity Coding:
  8. row
    2655
    values
    1. -For more details on SEER race/ethnicity groupings, please see Race and Hispanic Ethnicity Changes [https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/].
  9. row
    2656
    values
    1. -Incidence data for Hispanics and Non-Hispanics are based on the NAACCR Hispanic Latino Identification Algorithm (NHIA).
  10. row
    2657
    values
    1. -Rates for American Indians/Alaska Natives only include cases that are in a Purchased/Referred Care Delivery Area (PRCDA).
  11. row
    2658
    values
    1. Cancer Site Coding:
  12. row
    2659
    values
    1. -See SEER*Explorer Cancer Site Definitions [https://seer.cancer.gov/statistics-network/explorer/cancer-sites.html] for details about the cancer site coding used for SEER Incidence data.
source header rows
    1. SEER Explorer Data Archive, November 2024 SEER Submission (April 2025 Release)
    1. Chronic myeloproliferative disorders (CMD)
    1. SEER Relative Survival Rates by Time Since Diagnosis
    source missing marker
    -
    stage coding footnotes
      stage period caveat
      Source null
      stage system
      Source null

      Preserved source evidence · Independent clinical review pending · Not medical advice